Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma

•Data regarding direct oral anticoagulants (DOACs) appear safe for venous thromboembolism (VTE) treatment for patients with RCC on cabozantinib•No. of major bleeding events similar between no anticoagulant, low molecular weight heparin (LMWH) or DOAC groups.•The rate of new/recurrent VTE was similar among anticoagulant groups•Patients with a VTE had significantly worse survival than those without a VTE